InMed Pharmaceuticals to Focus on Pharmaceutical Programs Amid BayMedica Uncertainty

InMed Pharmaceuticals Inc. reported that the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" (the "Act") could have a material negative impact on BayMedica, a subsidiary of the Company. The Act may prohibit BayMedica's commercial business and inventory of rare, non-intoxicating cannabinoids if it comes into force on November 12, 2026. InMed remains focused on its core pharmaceutical programs, including INM-901 for Alzheimer's disease and INM-089 for age-related macular degeneration. BayMedica is evaluating alternative options to maintain compliance.